期刊文献+

原发性骨质疏松性椎体及股骨颈骨折病人血清基质金属蛋白酶-1与骨转换生化指标的关系 被引量:4

Relationship between serum MMP-1 level and ALP,NTX in patients with primary osteoporotic vertebral and femoral neck fracture
下载PDF
导出
摘要 目的探讨原发性骨质疏松性椎体及股骨颈骨折病人血清基质金属蛋白酶-1(MMP-1)与骨转换生化指标血清碱性磷酸酶(ALP)及Ⅰ型胶原氨基末端肽(NTX)的关系。方法用酶联免疫吸附试验(ELISA)测定34名骨质疏松椎体及股骨颈骨折病人的血清MMP-1、血清ALP和血清Ⅰ型胶原氨基末端肽(sNTX)水平。结果原发性骨质疏松性椎体及股骨颈骨折患者血清MMP-1与ALP及NTX无相关性;患者血清NTX水平较年龄匹配的骨质疏松组增高(P<0.0 5),血清MMP-1水平高于年龄匹配的正常对照组及骨质疏松组(P<0.05)。结论血清NTX水平增高可能为骨折的危险因素。原发性骨质疏松性椎体及股骨颈骨折患者血清MMP-1水平升高,可能为高骨代谢转换过程中的一种生化表现。 Objective To study the relationship between serum matrix metalloproteinase-1(MMP-1) level and Serum alkaline phosphatase(ALP),serum Cross-linked N-telopeptides of type I collagen(NTX) in patients with primary osteoporotic vertebral and femoral neck fracture.Methods Serum MMP-1,ALP and NTX were measured in 34 cases by ELISA.Results There was no significant correlation between MMP-1,ALP and NTX in primary osteoporotic vertebral and femoral neck fracture patients.Serum NTX was significantly higher in patients than in the age-matched patients with non-fracture osteoporosis(P〈0.05).Serum MMP-1 was significantly higher in patients than in normal controls and patients with non-fracture osteoporosis(P〈0.05).Conclusion Serum NTX may be a risk factor of osteoporotic vertebral and femoral neck fracture.Serum MMP-1 may be used as a bone turnover marker and a fracture risk factor in clinical diagnosis and treatment of osteoporosis patients.
出处 《临床军医杂志》 CAS 2011年第1期7-10,共4页 Clinical Journal of Medical Officers
关键词 基质金属蛋白酶-1 血清碱性磷酸酶 Ⅰ型胶原氨基末端肽 骨质疏松性骨折 matrix metalloproteinase-1 serum alkaline phosphatase serum Cross-linked N-telopeptides of type I collagen primary osteoporotic vertebral and femoral neck fracture
  • 相关文献

参考文献13

  • 1骨质疏松性骨折诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):458-459. 被引量:53
  • 2Swaminathan R.Biochemical markers of bone turnover[J].Clinica Chimica Acta,2001,313(1-2):95-105.
  • 3Gamero P,Sornay-Rendu E,Claustrar B,et al.Biochemical markers of Bone turnover,endogenous hormones and the risk of fracture in postmenopausal women:the OFELY study[J].J Bone Miner Res,2000,15(8):1526-l536.
  • 4周丽珍,向青,刘忠厚.合理使用骨质疏松症诊疗的骨代谢标志物指南(2004年版)[J].中国骨质疏松杂志,2004,10(4):397-404. 被引量:22
  • 5Bjarnaflon NH,Serker S,Duong T,et al.Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment postmenopausal osteoporosis[J].Osteoporosis Int 2001,12(11):922-930.
  • 6Eastell R,Hannon RA,Garnero P,et al.Relationship of early changes in bone resorption to the reduction infracture risk with risedronate:review of statistical analysis[J].J Bone Miner Res,2O07,22(11):1656-1660.
  • 7Delmas PD,Seeman E.Changes in bone mineral density little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy[J].Bone,2004,34(4):599-604.
  • 8Chapurlat RD,Gramero P,Breart G,et al.Afternoon sampled serum type I collagen breakdown product(serum CTX)predicts hip fracture in elderly women:results of the EPIDOS study[J].Bone,2000,27(2):283-286.
  • 9杨成宇,阮祥燕,刘忠厚.生化标志物在骨质疏松诊断、骨折预测和疗效观察中的应用[J].中国骨质疏松杂志,2003,9(4):371-380. 被引量:10
  • 10刘敬,许增禄,王计奎,徐园园,钱晓菁.绝经后骨质疏松症Ⅰ型胶原代谢的变化[J].解剖学报,2002,33(2):166-169. 被引量:7

二级参考文献61

  • 1[1]NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis and Therapy. JAMA 2001,285:785-795.
  • 2[2]Weinstein RS. True strength. J Bone Miner Res 2000,15:621-625.
  • 3[3]Chesnut Ⅲ CH, Rosen CJ for the Bone Quality Discussion Group. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 2001,16:2163-2172.
  • 4[4]Marcus R, Wong M, Heath Ⅲ H, et al. Antiresorptive treatment of posrmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002,23:16-37.
  • 5[5]Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001,19:331-337.
  • 6[6]Cummings SR, Karpf DB, Harris F, et al. Improvement of spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002,112: 282-289.
  • 7[7]Heaney RP. Is the paradigm shifting? Bone 2003,33:457-465.
  • 8[8]Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women; EPIDOS prospective study. J Bone Mineral Res 1996,11:1531-1538.
  • 9[9]Garnero P, Sornay-Rendu E, Claustrar B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fracture in postmenpausal women: the OFELY study. J Bone Miner Res 2000, 15: 1526-1536.
  • 10[10]Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures; a prospective study. Osteoporos Int 2000,11:76-82.

共引文献112

同被引文献37

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部